Literature DB >> 33623996

Spectrum of Kidney Diseases in Patients With Hepatitis C Virus Infection.

Shunhua Guo1, Meghan E Kapp2, Diego M Beltran3, Cesar Y Cardona4, Dawn J Caster5, Ronald R Reichel6, Agnes B Fogo2.   

Abstract

OBJECTIVES: To study the pathologic spectrum of kidney diseases in patients with hepatitis C virus infection (HCV+).
METHODS: Native kidney biopsy specimens in HCV+ patients were reviewed.
RESULTS: A total of 9,836 native kidney biopsy specimens were evaluated from January 2007 to December 2016, of which 273 (2.8%) were from HCV+ patients, and of these, 115 (42.1%) had diagnoses consistent with HCV-associated glomerulonephritis (GN). Non-HCV-associated kidney diseases comprised most diagnoses (158 cases, 57.9%) including non-immune complex-mediated kidney diseases (127 cases, 46.5%) and other immune complex-mediated glomerular diseases (31 cases, 11.4%). Forty-one (40.6%) patients had HCV-associated GN among 101 HCV+ patients from 2007 to 2011 vs 74 (43.0%) patients with HCV-associated GN among 172 HCV+ patients from 2012 to 2016. HCV-associated GN showed five morphologic patterns: focal proliferative (5.2%), diffuse mesangial proliferative (50.4%), diffuse membranoproliferative (28.7%), proliferative GN with crescentic lesions (7.8%), and membranous patterns (7.8%).
CONCLUSIONS: We found a spectrum of pathologic changes in renal biopsy specimens of HCV+ patients, with most having diseases unrelated to HCV infection, HCV-associated GN showing five morphologic patterns, and availability of effective HCV antiviral therapy not yet resulting in major changes in the spectrum of kidney diseases in these patients. © American Society for Clinical Pathology, 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cryoglobulinemia; HCV-associated glomerulonephritis; Hepatitis C virus (HCV); Kidney disease

Mesh:

Year:  2021        PMID: 33623996      PMCID: PMC9430452          DOI: 10.1093/ajcp/aqaa238

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   5.400


  28 in total

Review 1.  Hepatitis C virus infection and kidney disease: a meta-analysis.

Authors:  Fabrizio Fabrizi; Paul Martin; Vivek Dixit; Piergiorgio Messa
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

Review 2.  New developments in the diagnosis of fibrillary glomerulonephritis.

Authors:  Samih H Nasr; Agnes B Fogo
Journal:  Kidney Int       Date:  2019-04-09       Impact factor: 10.612

Review 3.  Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy.

Authors:  Jose M Morales; N Kamar; L Rostaing
Journal:  Contrib Nephrol       Date:  2012-01-30       Impact factor: 1.580

4.  New-onset hepatitis C virus-associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy
.

Authors:  Muriel Ghosn; Matthew B Palmer; Catherine E Najem; Danny Haddad; Peter A Merkel; Jonathan J Hogan
Journal:  Clin Nephrol       Date:  2017-05       Impact factor: 0.975

5.  Hepatitis C virus and its renal manifestations: a review and update.

Authors:  Nyan Latt; Nada Alachkar; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-07

6.  Fibrillary glomerulonephritis with hepatitis C viral infection and hypocomplementemia.

Authors:  Susan Ray; Kelly Rouse; Andrew Appis; Robert Novak; Nairmeen Awad Haller
Journal:  Ren Fail       Date:  2008       Impact factor: 2.606

Review 7.  Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis.

Authors:  Stephanie M Rutledge; Raymond T Chung; Meghan E Sise
Journal:  Hemodial Int       Date:  2018-04       Impact factor: 1.812

8.  A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients.

Authors:  Muhammad Idrees; Sheikh Riazuddin
Journal:  BMC Gastroenterol       Date:  2009-01-20       Impact factor: 3.067

9.  Hepatitis C as a potential cause of IgA nephropathy.

Authors:  A K Dey; A Bhattacharya; A Majumdar
Journal:  Indian J Nephrol       Date:  2013-03

10.  DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis.

Authors:  Samih H Nasr; Julie A Vrana; Surendra Dasari; Frank Bridoux; Mary E Fidler; Sihem Kaaki; Nathalie Quellard; Alexia Rinsant; Jean Michel Goujon; Sanjeev Sethi; Fernando C Fervenza; Lynn D Cornell; Samar M Said; Ellen D McPhail; Loren P Herrera Hernandez; Joseph P Grande; Marie C Hogan; John C Lieske; Nelson Leung; Paul J Kurtin; Mariam P Alexander
Journal:  Kidney Int Rep       Date:  2017-08-08
View more
  1 in total

Review 1.  Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.

Authors:  Iman Ibrahim Salama; Hala M Raslan; Ghada A Abdel-Latif; Somaia I Salama; Samia M Sami; Fatma A Shaaban; Aida M Abdelmohsen; Walaa A Fouad
Journal:  World J Hepatol       Date:  2022-06-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.